Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 10 · below the Ichimoku cloud · RSI 23 (oversold) · MACD below its signal · 1% above its 52-week low
None of the 29 investors followed here reported a position in ASPI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ASPI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Ryan Robert John AndrewDirector | Purchase at price 2.68 per share. | 15K | $40.20K |
| Sep 27, 2026 | Ryan Robert John AndrewDirector | Purchase at price 2.70 per share. | 8K | $21.60K |
| Sep 7, 2026 | Ainscow RobertChief Operating Officer | Sale at price 4.29 per share. | 8.4K | $36.22K |
| Sep 3, 2026 | Mann Paul ElliotChief Executive Officer | Sale at price 3.91 - 4.10 per share. | 251.3K | $999.24K |
| Sep 1, 2026 | Ainscow RobertChief Operating Officer | Sale at price 3.90 per share. | 25K | $97.63K |
| Sep 1, 2026 | Ainscow Donald GeorgeGeneral Counsel | Sale at price 3.89 per share. | 23.7K | $92.11K |
| Jun 30, 2026 | Kiessling HeatherChief Financial Officer | Sale at price 6.28 per share. | 23.1K | $145.22K |
| Jun 29, 2026 | Wider ToddDirector | Sale at price 6.12 - 6.25 per share. | 100K | $618.50K |
| Jun 29, 2026 | Gorley MichaelDirector | Sale at price 6.27 per share. | 30K | $188.10K |
| Jun 29, 2026 | Ainscow Donald GeorgeGeneral Counsel | Sale at price 6.14 per share. | 100K | $614.00K |
| Jun 7, 2026 | Ainscow RobertChief Operating Officer | Sale at price 7.00 per share. | 8.4K | $59.06K |
| Jun 2, 2026 | Mann Paul ElliotChief Executive Officer | Sale at price 7.76 - 8.29 per share. | 251.3K | $2.00M |
| May 27, 2026 | Ainscow RobertChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 800K | — |
| May 27, 2026 | Kiessling HeatherChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 840K | — |
| May 27, 2026 | Ainscow Donald GeorgeGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 400K | — |
| May 27, 2026 | Mann Paul ElliotChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 2.23M | — |
| Apr 15, 2026 | Moore DuncanDirector | Sale at price 5.20 per share. | 11.6K | $60.60K |
| Apr 15, 2026 | Ainscow RobertChief Operating Officer | Sale at price 5.20 per share. | 22.5K | $117.11K |
| Apr 14, 2026 | Kiessling HeatherChief Financial Officer | Sale at price 5.48 per share. | 23.1K | $126.67K |
| Mar 5, 2026 | Ainscow RobertChief Operating Officer | Sale at price 5.44 per share. | 8.4K | $45.89K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.5 | -15.8 | -17.2 | 19.0 | 47.9 | -20.1 | -35.7 | 0.5 | -34.1 | -21.9 | −61.3% | ||
| 2025 | 26.9 | -17.2 | -1.5 | 12.6 | 43.2 | -2.6 | 23.2 | 2.3 | 3.7 | 5.3 | -38.6 | -14.0 | +18.1% |
| 2024 | 36.9 | 55.5 | 8.4 | -23.2 | 61.2 | -40.1 | -13.4 | -10.6 | 17.3 | 151.4 | -20.6 | -18.4 | +153.1% |
| 2023 | -1.3 | 15.4 | -52.6 | -25.6 | -49.3 | 76.4 | 95.4 | 8.1 | -20.8 | 16.8 | 73.0 | -6.8 | +13.3% |
| 2022 | -26.1 | −26.1% |
Buy / hold / sell counts
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.